Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Otsuka Pharmaceuticals sales increase in 2010

Otsuka Pharmaceuticals sales increase in 2010

18th May 2010

The Otsuka group has published its financial results for the 12 months ending March 2010, reporting a 5.6 per cent year-on-year increase in pharmaceutical sales.

Net sales for Otsuka’s healthcare unit during the 2010 fiscal year came to 715.9 billion yen (5.3 billion pounds), up from 677.8 billion yen in 2009, with strong performance of the anti-psychotic agent Abilfy playing a major role.

Other treatments highlighted as having seen a good performance in the last year include the anti-gastritis and anti-gastric ulcer agent Mucosta and the oral selective vasopressin V2-receptor antagonist Samsca.

In addition to these product launches, Otsuka Pharmaceuticals also bolstered its pipeline in 2010 by agreeing a new cancer drug development collaboration with Bristol-Myers Squibb.

It also announced in December 2009 that it has extended its research collaboration with Galenea into schizophrenic illness until 2011.

The firm described its performance in 2010 as a sign of progress towards its mission “to continue contributing to the health of people around the world with innovative and creative products”.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.